To include your compound in the COVID-19 Resource Center, submit it here.

Contrave: Additional Phase III data

Data from 182 patients in the ambulatory blood pressure monitoring (ABPM) sub-study of the double-blind, placebo-controlled, U.S. Phase III COR-II (NB-303) trial in 1,496 patients showed that patients treated with Contrave maintained normal

Read the full 336 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE